ArticleVaccine2017
Economic impact of thermostable vaccines.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.Nature communications · 2023Trial
- Article
- Review
- Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule.Vaccines · 2026Article
- Antarctic microbial protein-rich extracts with cryoprotective potential for cell and viral preservation.Frontiers in microbiology · 2026Article
- Enhancing vaccine stability in transdermal microneedle platforms.Drug delivery and translational research · 2025Review
- Review
- Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines.Molecular pharmaceutics · 2024Review
- Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.Frontiers in immunology · 2024Article
- Multi-epitope vaccine candidates based on mycobacterial membrane protein large (MmpL) proteins againstOpen biology · 2023Article
- A robust optimization problem for drone-based equitable pandemic vaccine distribution with uncertain supply.Omega · 2023Article
- Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine.Heliyon · 2023Article
- When increasing vegetable production may worsen food availability gaps: A simulation model in India.Food policy · 2023Article
- Thermostable Vaccines in Veterinary Medicine: State of the Art and Opportunities to Be Seized.Vaccines · 2022Review
- Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.Frontiers in drug delivery · 2022Article
- A systems map of the economic considerations for vaccination: Application to hard-to-reach populations.Vaccine · 2021Article
- Development of thermostable vaccine adjuvants.Expert review of vaccines · 2021Review
- Lyophilized yeast powder for adjuvant free thermostable vaccine delivery.Applied microbiology and biotechnology · 2021Article
- How the use of vaccines outside the cold chain or in controlled temperature chain contributes to improving immunization coverage in low- and middle-income countries (LMICs): A scoping review of the literature.Journal of global health · 2021Article
- Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWhile our previous work has shown that replacing existing vaccines with thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase vaccine availability, the question remains whether this benefit would outweigh the additional cost of thermostable formulations.
methodsUsing HERMES simulation models of the vaccine supply chains for the Republic of Benin, the state of Bihar (India), and Niger, we simulated replacing different existing vaccines with thermostable formulations and determined the resulting clinical and economic impact. Costs measured included the costs of vaccines, logistics, and disease outcomes averted.
resultsReplacing a particular vaccine with a thermostable version yielded cost savings in many cases even when charging a price premium (two or three times the current vaccine price). For example, replacing the current pentavalent vaccine with a thermostable version without increasing the vaccine price saved from $366 to $10,945 per 100 members of the vaccine's target population. Doubling the vaccine price still resulted in cost savings that ranged from $300 to $10,706, and tripling the vaccine price resulted in cost savings from $234 to $10,468. As another example, a thermostable rotavirus vaccine (RV) at its current (year) price saved between $131 and $1065. Doubling and tripling the thermostable rotavirus price resulted in cost savings ranging from $102 to $936 and $73 to $808, respectively. Switching to thermostable formulations was highly cost-effective or cost-effective in most scenarios explored.
conclusionMedical cost and productivity savings could outweigh even significant price premiums charged for thermostable formulations of vaccines, providing support for their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.